Home » 2026 Biologics CDMO Public Market Update » Biologics Manufacturing Demand: Top Biotech Players’ Market Performance
Biologics Manufacturing Demand in 2025: Top Biotech Players’ Market Performance
Chapter of the 2026 Biologics CDMO Public Market Update
3 minute read
This article examines how leading biotechnology companies with significant biologics portfolios performed in 2025, highlighting the growing divergence in commercial outcomes across the sector. It explores how factors such as product mix, exposure to high-volume therapies, and pricing and competitive dynamics shaped both financial performance and equity market trends. The analysis also considers how these dynamics translate into biologics manufacturing demand, reinforcing the connection between commercial execution and production infrastructure needs.
In 2025, performance among leading biotechnology companies with substantial biologics portfolios reflected divergent commercial trajectories that were increasingly tied to product mix dynamics, competitive pressures, and manufacturing-intensive demand patterns. Equity and financial results among this cohort underscored how large-volume therapeutics, pricing pressures, and diversification of revenue streams informed market performance and outlook.
Click on the table to zoom in.
Among large-cap biologics leaders, Novo Nordisk continued to demonstrate underlying demand for its metabolic and GLP-1 products, with full-year 2025 net sales rising approximately 6.4%, supported by growth in both diabetes and obesity care franchises. Despite solid topline growth, Novo’s equity performance in late 2025 and early 2026 was weighed down by intensified pricing and competitive pressures, particularly in the US, and by expectations of slower sales growth in 2026 compared with prior years. This dynamic highlighted the tension between high-volume demand and market headwinds in a competitive biologics category.
Performance patterns among diversified biopharma peers reflected more stable, albeit uneven, outcomes. Amgen reported continued revenue and earnings growth in 2025 relative to 2024. Notably, broad product demand, including strong volume expansion for programs such as Repatha and growth in rare disease therapies, underpinned operational resilience. Among mid-cap innovators, Regeneron delivered modest revenue growth in 2025, with total annual revenues increasing year-over-year as the company maintained solid performance across its core therapeutic areas.
A broader theme across 2025 was that revenue visibility and product demand intensity were increasingly reflected in equity and financial outcomes. High-volume biologics that require consistent and scalable manufacturing, such as GLP-1 therapies and mature oncology or immunology biologics, provided clearer demand signals for both internal capacity planning and external outsourcing.
In aggregate, the performance of this cohort in 2025 reinforced the structural link between manufacturing demand and commercial execution. Stable or expanding revenue bases drove ongoing need for reliable biologics production infrastructure, supporting the continued relevance of mature contract development and manufacturing organization (CDMO) capacity in both upstream and downstream operations. At the same time, competitive and pricing pressures in key categories introduced a degree of caution into growth expectations, aligning capital markets scrutiny with operational realities in the biologics ecosystem.